Real-world observational study on pulmonary arterial hypertension: Italian cohort treated with macitentan and/or selexipag as a part of a combination treatment (INSPECTIO)

Key Points

Improved outcomes in pulmonary arterial hypertension were observed with combination treatment.
Treatment with macitentan and selexipag demonstrated notable effectiveness in managing symptoms.

Structured PICO

Does combination treatment including macitentan and/or selexipag improve non-invasive low-risk criteria in patients with pulmonary arterial hypertension?

Population

Italian cohort with pulmonary arterial hypertension (PAH)

Intervention

Macitentan and/or selexipag as a part of a combination treatment

Outcome

Increase in non-invasive low-risk criteria (disease stabilization) over 12 monthssurrogate

Real-world combination therapy with macitentan and/or selexipag in PAH patients is associated with an increase in non-invasive low-risk criteria, suggesting disease stabilization over 12 months.

Abstract

The INSPECTIO study supports the effectiveness of guideline-directed therapy and regular risk assessment to optimize treatment strategies in PAH. The increase in non-invasive low-risk criteria suggests a stabilization of disease over 12 months.

Bookmark

Cite This Study

D'Alto et al. (Tue,) studied this question.

synapsesocial.com/papers/69a7669bbadf0bb9e87ddadb https://doi.org/https://doi.org/10.1016/j.vph.2026.107585

Bookmark